DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02379507 |
Recruitment Status :
Completed
First Posted : March 5, 2015
Last Update Posted : March 5, 2015
|
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | January 13, 2015 | ||
First Posted Date ICMJE | March 5, 2015 | ||
Last Update Posted Date | March 5, 2015 | ||
Study Start Date ICMJE | January 2014 | ||
Actual Primary Completion Date | June 2014 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
Symptoms of Itching, Scaling, and Redness measured by Visual Analog Scale (VAS) [ Time Frame: 30 days ] Subjects completed the Visual Analog Scale for eczema symptoms - itching, scaling, and redness.
|
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Change History | No Changes Posted | ||
Current Secondary Outcome Measures ICMJE |
Size and Severity of Eczema Lesions measured by Dermatologic Assessments [ Time Frame: 30 days ] Dermatologic assessments for severity and size of lesions and Severity Scoring of Atopic Dermatitis (SCORAD) were assessed by a practitioner in the clinic.
|
||
Original Secondary Outcome Measures ICMJE | Same as current | ||
Current Other Pre-specified Outcome Measures | Not Provided | ||
Original Other Pre-specified Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title ICMJE | DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study | ||
Official Title ICMJE | DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study | ||
Brief Summary | This open-label, adaptive design study was designed to determine the efficacy of the study product in the treatment of eczema which would be assessed by the reduction of the appearance of skin lesions and symptoms associated such as itching, scaling and redness. | ||
Detailed Description | Eczema is an inflammatory skin disease characterized by itchy red rashes commonly found in the elbows or behind the knees. Eczema lesions may appear as collection of fluid in the skin (vesicles) or as gross thickening of the skin (lichenification) with redness. It is also associated with crusting, scaling, cracking, and swelling of the skin. Usually, it does not need medical treatment. However, a more severe form of eczema is referred to as atopic eczema or atopic dermatitis which occurs in childhood or early adulthood. The overall prevalence of this condition in Northern Europe is 15-20% of children aged 7-18 years. Atopic eczema greatly affects the quality of life of the individuals and in fact accounts for the highest scores when compared with other dermatological diseases. A child with eczema experiences itch and sleep disturbances, ostracism by other children, the need for special clothing and bedding, avoidance of physical activities such as swimming and the need for frequent application of ointments. Eczema is commonly treated with antihistamine pills and creams or ointments. Antihistamines and steroid creams control the itching and rash caused by severe eczema. It is also recommended that the skin be well lubricated to prevent it from becoming dry. A systematic review of randomized clinical trials on atopic eczema summarized the interventions for treating the condition which include pharmacological drug type (topical steroids), similar intervention type (dietary measures) or convenience (non-pharmacological treatments). Shea butter, which contains stearic acid, linoleic acid, and catechins (antioxidants), is processed from nut of the Vitellaria paradoxa tree. It is traditionally used as lotion for the skin and hair as it is considered an emollient and skin conditioning agent. It has also been of importance in soothing arthritic pains, reducing swelling, treating skin problems, and as antiseptic for wounds. Shea butter is also found in topical formulations used for inflammatory dermatoses such as psoriasis and atopic dermatitis. Shea butter consists of triterpene cinnamates and acetates and these were found to have anti-inflammatory activity which can help in the reduction of edema associated with eczema. Human clinical studies have demonstrated shea butter as skin aging treatment which regenerates skin and gives smoother, clearer skin. Wrinkles from photoaging were also diminished. Another trial showed that shea butter has cicatrizing action in 70% of cases of hand dermatitis, sun burns and scars. A cream with shea butter was also demonstrated to promote good moisturization of the skin compared to placebo. Macadamia nut oil is one of the most heart-friendly oils. It contains vitamin E, omega-3, omega-6, oleic, linoleic, and palmitoleic acids. Macadamia oil decreases low density lipoprotein levels and increases high density lipoprotein levels thus reducing risk of heart diseases. There are various benefits of macadamia oil on skin. It provides moisturization and anti-aging effects. Palmitoleic acid, which is commonly found in the skin, decreases as people age. Macadamia oil helps replace the lost compound to maintain youthful skin. Blemishes and scars are also removed with the help of macadamia oil. It has anti-inflammatory activity and antioxidant effects thus reducing free radicals on the skin and providing healing of skin conditions such as sunburns. This open-label, adaptive design study was designed to determine the efficacy of the study product in the treatment of eczema which would be assessed by the reduction of the appearance of skin lesions and symptoms associated such as itching, scaling and redness. |
||
Study Type ICMJE | Interventional | ||
Study Phase ICMJE | Phase 1 | ||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Supportive Care |
||
Condition ICMJE | Eczema | ||
Intervention ICMJE | Other: DEC033 Study Product
Apply twice daily
|
||
Study Arms ICMJE | Experimental: DEC033 Study Product
Apply twice a day
Intervention: Other: DEC033 Study Product
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status ICMJE | Completed | ||
Actual Enrollment ICMJE |
20 | ||
Original Actual Enrollment ICMJE | Same as current | ||
Actual Study Completion Date ICMJE | June 2014 | ||
Actual Primary Completion Date | June 2014 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender ICMJE |
|
||
Ages ICMJE | 18 Years to 70 Years (Adult, Older Adult) | ||
Accepts Healthy Volunteers ICMJE | Yes | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | Not Provided | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT02379507 | ||
Other Study ID Numbers ICMJE | DECI1200 | ||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement ICMJE | Not Provided | ||
Current Responsible Party | Medicus Research, LLC | ||
Original Responsible Party | Same as current | ||
Current Study Sponsor ICMJE | Medicus Research, LLC | ||
Original Study Sponsor ICMJE | Same as current | ||
Collaborators ICMJE | Not Provided | ||
Investigators ICMJE | Not Provided | ||
PRS Account | Medicus Research, LLC | ||
Verification Date | January 2015 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |